Eli Lilly’s orforglipron missed weight loss targets in a Phase 3 trial, but strong Q2 results and raised guidance highlight the company’s growth strength.
Latest Ratings for LLY
DateFirmActionFromTo Feb 2022Morgan StanleyMaintainsOverweight Feb 2022MizuhoMaintainsBuy Jan 2022Morgan StanleyMaintainsOverweight